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The neuroprotective role of adenosine and the deregulation of adenosine receptors in Alzheimer’s dis-
ease (AD) have been extensively studied in recent years. However, little is known about the involvement
of purine metabolism in AD. We started by analyzing gene expression in the entorhinal cortex of human
controls and AD cases with whole-transcript expression arrays. Once we identiﬁed deregulation of the
cluster purine metabolism, messenger RNA expression levels of 23 purine metabolism genes were
analyzed with qRT-PCR in the entorhinal cortex, frontal cortex area 8, and precuneus at stages I-II, III-IV,
and V-VI of Braak and Braak and controls. APRT, DGUOK, POLR3B, ENTPD3, AK5, NME1, NME3, NME5,
NME7, and ENTPD2 messenger RNAs were deregulated, with regional variations, in AD cases when
compared with controls. In addition, liquid chromatography mass spectrometry based metabolomics in
the entorhinal cortex identiﬁed altered levels of dGMP, glycine, xanthosine, inosine diphosphate, gua-
nine, and deoxyguanosine, all implicated in this pathway. Our results indicate stage- and region-
dependent deregulation of purine metabolism in AD.
 2014 Elsevier Inc. All rights reserved.1. Introduction
Alzheimer’sdisease (AD) is a humanage-relatedbiological process
which causes progressive degeneration of the brain and which is
characterized clinically by cognitive impairment and dementia, and
neuropathologically by the variable combination of 2 hallmarks,
neuroﬁbrillary tangles composed of abnormally phosphorylated, and
conformed and truncated tau, and senile plaques with a core of the
altered cleavage of amyloid precursor protein leading to the deposi-
tion of b-amyloid (Duyckaerts and Dickson, 2011; Haass and Selkoe,
2007; Lowe et al., 2008). In addition to the pathologic hallmarks of
AD, several other abnormalities have been reported in AD, including
mitochondrial malfunction; increased oxidative stress and oxidative/
nitrosative damage to nucleic acids, proteins, and lipids; energy
metabolism failure; altered composition of lipids in lipid rafts;ology, Service of Pathology,
8907 Hospitalet de Llobregat,
.
ll rights reserved.neuroinﬂammation; and endoplasmic reticulum stress, impaired
ubiquitin-proteasome system, and autophagy (Ferrer, 2012).Multiple
signaling and neurotransmitter pathways are altered compromising
neuron-neuron interactions and glial-neurons interactions.
Purines are heterocyclic double-ring aromatic organic molecules;
primary purine adenine and guanosine nucleobases, together with
one-ring primary pyrimidine nucleobases cytosine, thymidine, and
uracil, are the core of DNA, RNA, nucleosides, and nucleotides.
Adenosine and guanosine are purine ribonucleosides resulting from
the b-N9-glycosidic bound to adenine or guanine and ribose,
respectively. When adenine and guanine are attached to the C1 car-
bon of a deoxyribose ring, the resulting compounds are deoxy-
adenosine and deoxyguanosine, respectively. Nucleotides result from
the incorporation of phosphate groups in nucleosides: Adenosine
monophosphate (AMP), adenosine diphosphate, Adenosine triphos-
phate (ATP), guanosine monophosphate, guanosine diphosphate,
guanosine triphosphate, and cyclic forms cAMP and cGMP are pri-
mary purine-derived nucleotides. Modiﬁed purine nucleobases
hypoxantine and xanthine result from the replacement of the amino-
group by a carbonyl-group from adenine and guanine, respectively,
whereas methyl-guanine results from the incorporation of a methyl
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inosine, xanthosine, andmethyl-guanosine, respectively. Nucleotides
participate in a wide variety of crucial metabolic pathways including
energy metabolism and cell signaling. In addition, purine bases are
incorporated to other molecules to form cofactors of several enzy-
matic reactions such as coenzyme A, ﬂavin adenine dinucleotide
(FAD), nicotinamide adenine dinucleotide (NADþ), nicotinamide
adenine dinucleotide phosphate (NADPþ), and the corresponding
reduced forms FADH2, NADH, and NADPH. S-Adenosyl methionine is
made from ATP and methionine by methionine adenosyltransferase
and is involved in the transfer ofmethyl groups to distinct substrates,
includingnucleicacids,proteins, lipids, andmetabolites. Inadditionto
intracellular signaling, purines and their products may function as
extracellular signals acting on other cells, either between neurons or
neurons and glial cells equipped with appropriate receptors (Ipata
et al., 2011). Adenosine is responsible for regulating, integrating and
ﬁne-tuning neuronal activity, and inﬂuencing relevant brain func-
tions, including sleep and arousal, cognition and memory, and
neuronal damage and degeneration, by acting as an extracellular
molecular via speciﬁc adenosine receptors (Rahman, 2009). Adeno-
sine receptor signaling also modulates permeability of the blood-
brain barrier (Carman et al., 2011). Adenosine exerts its function by
binding adenosine receptors which are G-protein-coupled receptors
(A1, A2A, A2B, and A3) that can inhibit (A1 and A3) or enhance (A2)
neuronal communication through neurotransmitter release (Ribeiro
et al., 2003). Several indirect data suggest altered purine meta-
bolism in AD. Energy metabolism dependent on mitochondrial
function and ATP production ismarkedly altered in AD (Ferreira et al.,
2010; Ferrer, 2009). In addition, oxidative damage toDNA andRNA, as
revealed by the increase in 8-hydroxyguanosine, is found in the brain
in AD (Lovell and Markesbery, 2008; Lovell at al., 2011; Markesbery
and Lovell, 2006; Nonumura et al., 2012; Weidner et al., 2011).
Regarding purine neurocrine factors, adenosine receptors have
attracted interest because of the neuroprotective effects of adenosine
in several neurologic disorders (Boisson, 2008; Ribeiro et al., 2003).
Experiments carried out with cell lines have demonstrated that A1
activationmediates the production of soluble forms of b-amyloid and
tau phosphorylation (Angulo et al., 2003). Furthermore, blockade of
A2A receptors in rat cultured cerebellar granule neurons with Ab25-
35 prevents b-amyloid-induced neurotoxicity (Dall’Igna et al., 2003),
suggesting that thepresence of A2A is critical forAb toxicity (Rahman,
2009). cAMP is an endogenousmodulator of the b-amyloid precursor
protein metabolism (Canepa et al., 2013). Decreased levels of A1 re-
ceptors and altered binding of adenosine agonists and antagonists to
A1 receptors have been observed in the molecular layer of the CA1
region of the hippocampus in AD (Ulas et al., 1993). In contrast,
upregulation ofA1 andA2A receptors has been reported in the frontal
cortex in AD (Albasanz et al., 2008).
Direct alterations of purine metabolism in AD have also been
detected by metabolomics in the ventricular cerebrospinal ﬂuid at
postmortem (Kaddurah-Daouk et al., 2011) and in the cerebrospinal
ﬂuid in living individuals (Isobe et al., 2010; Kaddurah-Daouk et al.,
2013; Jové et al., 2014). Only a limited number of metabolomic
studies have been carried out in AD brains (Jové et al., 2014).
However, little is known about possible alterations in the
expression of genes encoding enzymes involved in purine meta-
bolism in AD brains. This information would permit a better un-
derstanding of the primary regulation of purine-related genes and
their possible implications in the pathogenesis of the disease. First,
functional genomics in a short series of AD cases revealed a
deregulated cluster of genes involved in purine metabolism in the
entorhinal cortex in AD brains. Second, the expression of selected
genes was analyzed in the enthorinal cortex, frontal cortex area 8,
and precunneus at stages I-II, III-IV, and V-VI of Braak and Braak,
compared with controls. Finally, metabolomics was applied to thestudy of the entorhinal cortex to increase the understanding of
functional implications of deregulated purine metabolism. We fully
understand that the postmortem study of the human brain has
certain limitations because it cannot be manipulated premortem,
and because it is subject to degradation processes. Nevertheless, the
study of the human postmortem brain cannot be replaced by any
model, and it represents an invaluable source of knowledge.
2. Methods
2.1. Human cases
Brain tissue was obtained from the Institute of Neuropathology
HUB-ICO-IDIBELL Biobank following the guidelines of Spanish legis-
lation on this matter and the approval of the local ethics committee.
The postmortem interval between death and tissue processing was
between 3 and 20 hours. One hemisphere was immediately cut in
coronal sections, 1-cm thick, and selected areas of the encephalon
were rapidly dissected, frozen on metal plates over dry ice, placed in
individual air-tight plastic bags, numbered with water-resistant ink,
and stored at 80 C until use for biochemical studies. The other
hemisphere was ﬁxed by immersion in 4% buffered formalin for
3 weeks for morphologic studies. Neuropathologic study in all cases
was routinely performedon20dewaxedparafﬁn sections comprising
different regions of the cerebral cortex, diencephalon, thalamus, brain
stem, and cerebellum, which were stained with hematoxylin and
eosin, Klüver-Barrera, and for immunohistochemistry to microglia,
glial ﬁbrillary acidic protein, b-amyloid, phosphorylated tau (clone
AT8), a-synuclein, TDP-43, ubiquitin, and p62.
Neuropathologic diagnosis of AD was based on the classiﬁcation
of Braak and Braak (Braak and Braak,1991,1999) adapted to parafﬁn
sections (Braak et al., 2006).
Cases with combined pathologies (i.e., Parkinson’s disease,
tauopathy, vascular diseases, and metabolic syndrome) were
excluded from the present study. Age-matched control cases had
not suffered from neurologic or psychiatric diseases, or metabolic
diseases (including metabolic syndrome), and did not have abnor-
malities in the neuropathologic examination (excepting Braak and
Braak stages I-II).
Cases used in the present study for messenger RNA (mRNA)
expression corresponded to 23 AD stages III-IV (12men,11women),
35 AD stages V-VI (20 men, 15 women), and 34 controls (21 men, 13
women). Three regions were examined: entorhinal cortex, frontal
cortex, and precuneus. However, whole-transcript expression ar-
rays were carried out in the entorhinal cortex in 5 controls and 5 AD
cases stage V-VI. These cases were accepted once the RNA integrity
number (RIN) values were considered sufﬁcient to perform RNA
studies. A summary of the cases used for mRNA studies are shown
in Table 1.
In addition to these cases, AD samples (n ¼ 16) of the entorhinal
cortex stages from stages ranging AD I-II (3 women and 4 men, aged
between 55 and 79 years), AD III-IV (2 men and 2 women, aged be-
tween68 and80years), andV-VI (1womenand4men, agedbetween
75 and 87 years) in comparisonwith control cases (n¼ 4)were added
for metabolomics studies. The postmortem delay in all these cases
was between 3 hours 45 minutes and 9 hours 30 minutes, and
particular attention was paid to include cases with short or sudden
agonic state, renal, hepatic, and respiratory insufﬁciency, infections
and neoplasia, in addition to those criteria referred previously.
2.2. Whole-transcript expression arrays
RNA samples from entorhinal cortex of control and AD cases
were analyzed using the Affymetrix microarray platform and the
Genechip Affymetrix Human Exon 1.0 ST Array. This array analyzes
Table 1
Summary of the main clinical and pathologic features of the cases used for mRNA expression studies
Case Gender Age
(y)
PMD Neuropathologic
diagnosis
RIN values
EC PC FC
1 M 75 3 h C 6.5
2 M 62 3 h C 7.2
3 M 67 5 h C 7
4 M 55 16 h C 7.4
5 M 56 5 h C 7.1
6 M 57 5 h 20 min C 7.3
7 W 66 4 h 15 min C 6.9 7
8 M 49 7 h C 8.2
9 M 53 3 h C 7.7
10 M 59 7 h 5 min C 7.9
11 M 46 9 h 35 min C 7.2
12 M 56 3 h 50 min C 7.1
13 M 52 4 h 40 min C 7.9
14 W 52 5 h 45 min C 6.6
15 W 71 8 h 30 min C 7.4
16 M 61 3 h 40 min C 6.9 7.7
17 M 65 2 h 15 min C 7.3 7.8
18 W 79 3 h 35 min C 7.3
19 W 79 3 h 35 min C 8
20 W 79 6 h 25 min C 7.1
21 W 79 6 h 25 min C 6.4
22 M 64 8 h 35 min C 7.7
23 W 64 5 h C 6.9 8
24 W 77 3 h 15 min C 7.2
25 W 77 3 h 15 min C 7
26 M 79 4 h 15 min C 7.2 6.6
27 W 76 5 h 45 min C 8.3
28 M 83 4 h 30 min C 8 8
29 M 71 5 h 15 min C 6.6 6.8
30 W 86 4 h 15 min C 7.4
31 W 86 4 h 15 min C 8.4
32 M 85 3 h 45 min C 8.2
33 M 77 2 h 55 min C 7 8.2
34 M 80 3 h 30 min C 7.3 6.5
35 M 83 18 h AD III 6.8
36 W 77 11 h 30 min AD III 6.7
37 M 90 2h 30 min AD III 8.8
38 M 81 4 h AD III 6.5
39 M 81 4 h AD III 7.4
40 M 82 3 h 45 min AD III 6.8
41 W 76 9 h 50 min AD III 8.3
42 M 69 13 h 10 min AD III 7.7 6.9
43 M 69 13 h 10 min AD III 8.8
44 M 80 4 h 20 min AD III 6.7
45 W 67 6 h 10 min AD III 6.6
46 W 67 6 h 10 min AD III 6.4
47 W 90 4 h AD III 6.9 6.9
48 W 79 3 h 35 min AD III 7.7 7.7
49 W 79 3 h 35 min AD III 8.7
50 M 77 5 h 40 min AD III 6.4 6.7
51 W 82 3 h 05 min AD III 6.4 7.4
52 M 75 3 h 25 min AD III 7.3 7
53 M 75 6 h 10 min AD IV 6.8
54 W 90 9 h 55 min AD IV 6.5
55 W 81 5 h AD IV 6.4 7.2
56 W 81 5 h AD IV 7.3
57 M 79 4 h 15 min AD IV 7
58 M 82 10 h AD V 6.4
59 W 86 10 h AD V 7
60 M 78 19 h AD V 6.9
61 M 81 3 h 45 min AD V 7.3
62 W 82 1 h 45 min AD V 7.8
63 M 72 2 h 45 min AD V 7
64 M 77 8 h AD V 7.7
65 W 96 17 h 35 min AD V 7
66 M 79 7 h 30 min AD V 6.7
67 M 73 4 h 30 min AD V 7.4 8.5
68 W 85 16 h 15 min AD V 6.4 6.9
69 W 85 16 h 15 min AD V 7.9
70 W 74 5 h 30 min AD V 7.5 8.7
71 M 93 3 h AD V 7.6
72 M 93 3 h AD V 7.8 7.8
(continued on next page)
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Table 1 (continued )
Case Gender Age
(y)
PMD Neuropathologic
diagnosis
RIN values
EC PC FC
73 W 81 5 h 15 min AD V 8.5
74 M 75 11 h 30 min AD V 6.3 6.4
75 M 82 03 h 45 min AD V 7.4
76 M 82 03 h 45 min AD V 7.8 9.1
77 M 77 16 h AD V 6.8 6.5
78 M 92 7 h 45 min AD V 6.8
79 W 87 5 h 15 min AD V 6.4
80 W 93 6 h AD V 7.4
81 M 80 6 h 30 min AD V 7.9
82 M 61 8 h 15 min AD V 6.6
83 W 85 5 h AD V 6.8
84 W 85 12 h 10 min AD VI 6.7
85 W 86 20 h 35 min AD VI 7.5
86 W 67 8 h AD VI 7
87 W 67 8 h AD VI 8.2
88 M 82 5 h AD VI 6.7
89 M 84 5 h AD VI 7.6
90 W 85 5 h 45 min AD VI 6.9
91 M 63 8 h AD VI 7
92 M 75 6 h 40 min AD VI 6.7
Key: AD, Alzheimer’s disease; C, control; EC, entorhinal cortex; FC, frontal cortex; M, man; mRNA, messenger RNA; PC, precuneus; PMD, postmortem delay; RIN, RNA integrity
number; W, woman.
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array, with probes covering several exons on the target genes.
Starting material was 200 ng of total RNA of each sample. Quality of
isolated RNA was ﬁrst measured with Bioanalyzer Assay (Agilent).
Sense single-stranded DNA suitable for labelingwas generated from
total RNA with the Ambion WT Expression Kit from Ambion
(Carlsbad, CA, USA), according to the manufacturer’s instructions.
Sense single-stranded DNA was fragmented, labeled, and hybrid-
ized to the arrays with the GeneChip WT Terminal Labeling and
Hybridization Kit from Affymetrix (Affymetrix, Santa Clara, CA,
USA). Chips were processed on an Affymetrix Gene Titan platform.
Microarray Data normalization and differential expression analysis
preprocessing of raw data, and statistical analyses, were performed
using Bioconductor packages in R programming environment
(Gentleman et al., 2004). CEL ﬁles were read from Affymetrix arrays
and corrected for the background. Resulting data were summarized
and normalized with the microarray A method implemented in theTable 2
TaqMan probes used for the study of expression of purine metabolism enzymes, includin
Gene Full name
ADA Adenosine deaminase
AK1 Adenylate kinase 1
AK2 Adenylate kinase 2
AK4 Adenylate kinase 4
AK5 Adenylate kinase 5
AK7 Adenylate kinase 7
APRT Adenine phosphoribosyltransferase
DGUOK Deoxyguanosine kinase
ENTPD1 Ectonucleoside triphosphate diphosphohydrolase 1
ENTPD2 Ectonucleoside triphosphate diphosphohydrolase 2
ENTPD3 Ectonucleoside triphosphate diphosphohydrolase 3
GUS-B B-glucuronidase
NME1 Non-metastatic cells 1, protein (NM23A) expressed in (nucl
NME3 Non-metastatic cells 3, protein expressed in (nucleoside-dip
NME4 Non-metastatic cells 4, protein expressed in (nucleoside-dip
NME5 Non-metastatic cells 5, protein expressed in (nucleoside-dip
NME6 Non-metastatic cells 6, protein expressed in (nucleoside-dip
NME7 Non-metastatic cells 7, protein expressed in (nucleoside-dip
NT5C 50 , 30-nucleotidase, cytosolic
NT5E 50-nucleotidase, ecto (CD73)
NUDT1 Nudix (nucleoside diphosphate-linked moiety X)-type motif
PNP Purine nucleoside phosphorylase
POLR3B Polymerase (RNA) III (DNA directed) polypeptide B
PRUNE Prune homolog (drosophila)Bioconductor Limma package (Smyth, 2005). Furthermore, the fold
change and standard errorswere estimated by ﬁtting a linearmodel
(using the lmFit function in Limma package) for each gene given the
groups of arrays. Genes with empirical Bayes t test, p-values at a
level of 0.05 were selected.
2.3. RNA puriﬁcation
PuriﬁcationofRNA fromthe right frontal cortex area8, entorhinal
cortex, and precuneus of AD samples and age-matched controls was
carried out with RNeasy Lipid Tissue Mini Kit (Qiagen, Hilden,
Germany) following the protocol provided by the supplier. During
puriﬁcation, samples were treated with RNase-free DNase Set
(Qiagen) for 15minutes to avoid extraction and later ampliﬁcation of
genomic DNA. The concentration of each sample was measured at
340 nm using a NanoDrop 2000 spectrophotometer (Thermo Sci-
entiﬁc, Waltham, Massachussets, USA). RNA integrity was assessedg probes for normalization (GUS-b)
Sequence of TaqMan probes
AGTTTAAAAGGCTGAACATCAATGC
AGTTTGAGCGACGGATTGGACAGCC
GGCAGGCAGAAATGCTCGATGACCT
ACTGGCTCCTTGATGGTTTTCCTAG
CTTTTGAGGACCAAATCTGTACCCC
GGAGACGTACTCTGCCATCTCTCAA
CGCATCGACTACATCGCAGGCCTAG
GCAACATTGCTGTGGGAAAGTCCAC
TCATTGGCAAGATCCAGGGCAGCGA
CCCGCCCTCAAGTATGGCATCGTCC
TGAAAAAGAAGTGGGGAATAGCAGC
GCTACTACTTGAAGATGGTGATCGC
eoside-diphosphate kinase) TGTTACCATCCCCGACCATCTGATT
hosphate kinase) ATCGAGGTTGGCAAGAACCTGATTC
hosphate kinase) GTCCACATCAGCAGGAATGTCATCC
hosphate kinase) TTTTATGTTTCCTGAAGTGATTGTT
hosphate kinase) CCACTGATTCTGGAGGCTGTTCATC
hosphate kinase) CTGATCCTGAAATTGCCCGGCATTT
TGCGGCCCGACCTGGCGGATAAAGT
TTCTTTACACAGGCAATCCACCTTC
1 ATGGGGCTAGGAGGGAGCTGCAGGA
GGGAGCAGACGCTGTTGGCATGAGT
GGTATTCTGGCTGGTGCCATTACTG
CCCTTCTGCATGGAACCATCATCCT
Fig. 1. Hierarchical clustering heat map of expression intensities of mRNA array transcripts of purine metabolism deregulated genes (on the y axis) in the entorhinal cortex in AD
versus controls (on the x axis). A separation between AD (except 1 AD case) and control proﬁles indicates modiﬁcation of genes linked to purine metabolism in the entorhinal cortex
in AD. Abbreviations: AD, Alzheimer’s disease; mRNA, messenger RNA.
B. Ansoleaga et al. / Neurobiology of Aging xxx (2014) 1e13 5with the RINdeterminedwith theAgilent 2100Bioanalyzer (Agilent,
Santa Clara, CA, USA). RIN values for each sample are shown in
Table 1.
2.4. Retrotranscription reaction
Retrotranscription reaction of RNA samples selected based on
their RIN values was carried out with the High-Capacity cDNA
Archive kit (Applied Biosystems, Foster City, CA, USA) following the
guidelines provided by themanufacturer and using Gene Amp 9700
PCR System thermocycler (Applied Biosystems). A parallel reaction
for 1 RNA samplewas processed in parallel in the absence of reverse
transcriptase to rule out DNA contamination.
2.5. Real-time polymerase chain reaction
Polymerase chain reaction (PCR) assays were conducted in
duplicate on cDNA samples obtained from the retrotranscription
reaction, diluted 1:20 in 384-well optical plates (Kisker Biotech,
Steinfurt, Germany) utilizing the ABI Prism 7900 HT Sequence
Detection System (Applied Biosystems). Parallel ampliﬁcation re-
actions were carried out using 20 TaqMan Gene Expression Assays
for purine metabolism enzymes and 2 TaqMan Universal PCR
Master Mix (Applied Biosystems). TaqMan probes used in the study
are shown in Table 2. The reactions were performed following the
parameters: 50 C for 2 minutes, 95 C for 10 minutes, 40 cycles at
95 C for 15 seconds, and 60 C for 1 minute. TaqMan PCR data were
captured using the Sequence Detection Software (SDS version 2.2,
Applied Biosystems). Subsequently, threshold cycle (CT) data for
each sample were analyzed with the double delta CT (DDCT)
method. First, delta CT (DCT) values were calculated as the
normalized CT values of each target gene in relation to theendogenous control b-glucuronidase (GUS-b). X-prolyl amino-
pepidase P1 (XPNPEP1) was also used as a putative housekeeping
gene with suboptimal results, and therefore, XPNPEP1 was dis-
carded. Second, DDCT values were obtained from the DCT of each
sample minus the mean DCT of the population of control samples
(calibrator samples). The fold change was determined using the
equation 2DDCT. Mean fold-change values for every region and
stage between AD and age-matched controls were analyzed with
the Student t test using the Statgraphics Statistical Analysis and
Data Visualization Software version 5.1. Differences between
groups were considered statistically signiﬁcant at * p < 0.05, ** p <
0.01, and *** p < 0.001.2.6. Metabolomic analyses
Tissue samples (50e70 mg) were homogenized using 20 vol-
umes of cold methanol, containing 1 mM butylhydroxytoluene as
antioxidant. Then, samples were incubated for 1 hour at 20 C and
centrifuged for 3 minutes at 12,000 g. The supernatant was recov-
ered, evaporated using a Speed Vac (Thermo Fisher Scientiﬁc, Bar-
celona, Spain), and resuspended in water 0.4% acetic acid:methanol
(1:1). Metabolite extracts were subjected to mass spectrometry
using an HPLC 1290 series coupled to an ESI-Q-TOF MS/MS 6520
(Agilent Technologies, Santa Clara, CA, USA). Speciﬁcally, 2 mL of
sample extract was applied to a reversed-phase column (Zorbax SB-
Aq 1.8 mm 2.1  50 mm; Agilent Technologies, Barcelona, Spain)
equipped with a precolumn (Zorbax-SB-C8 Rapid Resolution Car-
tridge 2.130 mm 3.5 mm) with a column temperature set at 60 C.
The ﬂow rate was 0.6 mL/min. Solvent A was composed of water
containing 0.2% acetic acid, and solvent B was composed of meth-
anol 0.2% acetic acid. The gradient started in 2% B and increased to
Fig. 2. mRNA expression levels of deregulated genes of purine metabolism in the entorhinal cortex in control and AD cases stages V-VI as determined by TaqMan PCR assays.
Expression values for the distinct probes were normalized with GUS-b. Mean fold-change values of each group are compared with Student t test and differences are considered
statistically signiﬁcant at * p < 0.05; ** p < 0.01; *** p < 0.001. Abbreviations: AD, Alzheimer’s disease; GUS-b, b-glucuronidase; mRNA, messenger RNA; PCR, polymerase chain
reaction.
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established in 5 minutes, as previously described (Jové et al., 2011).
Data were collected in positive and negative electrospray mode
time of ﬂight operated in full-scan mode at 100e3000 m/z in an
extended dynamic range (2 GHz), using N2 as the nebulizer gas (5 L/
min, 350 C). The capillary voltage was 3500 V with a scan rate of 1
scan/s. The ESI source used a separate nebulizer for the continuous,
low-level (10 L/min) introduction of reference mass compounds:
121.050873, 922.009798 (positive ion mode) and 119.036320,
966.000725 (negative ion mode), which were used for continuous,
online mass calibration. The Masshunter Data Analysis Software
A.02.00 (Agilent Technologies, Barcelona, Spain) was used to collect
the results, and the Masshunter Qualitative Analysis Software (Agi-
lent Technologies, Barcelona, Spain) was used to obtain the molec-
ular features of the samples, representing different, co-migrating
ionic species of a givenmolecular entity using theMolecular Feature
Extractor algorithm (Agilent Technologies, Barcelona, Spain), as
described (Jové et al., 2011; Sana et al., 2008). Finally, theMasshunterMass Proﬁler Professional Software (Agilent Technologies, Barce-
lona, Spain) was used to perform a nontargeted metabolomic anal-
ysis of the extracted features.We selected samples with aminimum
absolute abundance of 5000 counts and with a minimum of 2 ions.
Multiple charge states were not considered. Compounds from
different samples were aligned using an retention time window of
0.1% 0.15 minutes and a mass window of 5.0 ppm2.0 mDa. Only
common features (found in at least 75% of the samples of the same
condition) were analyzed, correcting for individual bias. Data for
hierarchical clustering were obtained using this software. The
masseswith signiﬁcant differences in abundance (determined using
a Student t test; fold change2,p<0.05,multiple testing correction:
Benjamini-Hochberg) were searched against the various databases.
We performed identiﬁcation of differential metabolites using the
database PCDL from Agilent (Agilent Technologies), which uses
retention times in a standardized chromatographic system as an
orthogonal searchableparameter to complementaccuratemassdata
Fig. 3. mRNA expression levels of deregulated genes of purine metabolism in the frontal cortex area 8 in control and AD cases as determined by TaqMan PCR assays. Expression
values for the distinct probes are normalized with GUS-b. Mean fold-change values of each group are compared with Student t test and differences are considered statistically
signiﬁcant at * p < 0.05 and ** p < 0.01. (A) Comparison between controls and AD stages III-IV. (B) Comparison between controls and AD stages V-VI. Abbreviations: AD, Alzheimer’s
disease; GUS-b, b-glucuronidase; mRNA, messenger RNA; PCR, polymerase chain reaction.
Table 3
mRNA expression levels of total purine metabolism enzymes in control and AD cases in the entorhinal cortex as determined by TaqMan PCR assays. Expression levels of
controls, AD III-IV, and AD V-VI cases using GUS-b for normalization
Probe C AD III-IV AD V-VI C versus AD III-IV C versus AD V-VI
ADA 1.04  0.32 0.99  0.31 0.81  0.29 d d
AK1 1.04  0.29 1.05  0.32 1.08  0.20 d d
AK2 1.01  0.16 0.98  0.15 0.98  0.13 d d
AK4 1.07  0.38 1.03  0.30 0.94  0.24 d d
AK5 1.04  0.30 0.98  0.32 0.78  0.31 d Y*
AK7 1.13  0.58 0.97  0.39 1.10  0.86 d d
APRT 1.03  0.23 0.87  0.21 0.76  0.19 d Y**
DGUOK 1.04  0.29 1.00  0.29 0.81  0.13 d Y**
ENTPD1 1.05  0.30 1.02  0.19 1.20  0.31 d d
ENTPD2 1.06  0.33 1.17  0.33 1.48  0.53 d [*
ENTPD3 1.22  0.76 0.99  0.42 0.66  0.31 d Y*
NME1 1.01  0.17 0.93  0.26 0.83  0.22 d Y*
NME3 1.02  0.19 0.92  0.26 0.75  0.14 d Y***
NME4 1.03  0.27 1.06  0.21 1.03  0.21 d d
NME5 1.11  0.49 1.09  0.36 0.81  0.30 d Y*
NME6 1.03  0.25 1.04  0.25 0.95  0.18 d d
NME7 1.03 0.29 0.89  0.28 0.82  0.24 d Y*
NT5C 1.01  0.13 1.05  0.22 1.01  0.22 d d
NT5E 1.11  0.50 1.09  0.54 0.84  0.25 d d
NUDT1 1.08  0.34 0.95  0.19 0.95  0.16 d d
PNP 1.10  0.49 1.11  0.48 0.97  0.44 d d
POLR3B 1.09  0.46 0.83  0.30 0.69  0.20 d Y**
PRUNE 1.04  0.28 1.15  0.14 0.91  0.19 d d
Student t test *p < 0.05, **p < 0.01, and ***p < 0.001.
Key: AD, Alzheimer’s disease; C, control; GUS-b, b-glucuronidase; mRNA, messenger RNA; PCR, polymerase chain reaction.
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Table 4
mRNA expression levels of total purine metabolism enzymes in control and AD cases in frontal cortex area 8 as determined by TaqMan PCR assays. Expression levels of controls,
AD III-IV, and AD V-VI cases using GUS-b for normalization
Probe C AD III-IV AD V-VI C versus AD III-IV C versus AD V-VI
ADA 1.07  0.40 1.25  0.56 1.14  0.40 d d
AK1 1.11  0.46 1.30  0.19 1.41  0.56 d d
AK2 1.01  0.17 1.11  0.12 1.06  0.22 d d
AK4 1.14  0.52 1.35  0.33 1.12  0.52 d d
AK5 1.05  0.36 0.93  0.25 0.78  0.38 d Y*
AK7 1.05  0.32 1.24  0.34 1.22  0.42 d d
APRT 1.06  0.35 1.21  0.20 1.09  0.50 d d
DGUOK 1.09  0.42 1.24  0.27 1.15  0.52 d d
ENTPD1 1.08  0.40 1.30  0.41 1.29  0.55 d d
ENTPD2 1.00  0.41 1.55  0.42 1.19  0.41 [** d
ENTPD3 1.18  0.66 0.90  0.38 0.81  0.55 d d
NME1 1.09  0.48 1.11  0.33 0.98  0.58 d d
NME3 1.04  0.29 1.50  0.36 1.14  0.43 [** d
NME4 1.04  0.32 1.27  0.23 1.10  0.54 d d
NME5 1.10  0.49 1.10  0.27 0.95  0.53 d d
NME6 1.06  0.38 1.27  0.35 1.07  0.48 d d
NME7 1.09  0.45 1.06  0.24 0.97  0.54 d d
NT5C 1.05  0.32 1.36  0.52 1.10  0.25 d d
NT5E 1.16  0.62 1.44  0.60 1.34  0.75 d d
NUDT1 1.03  0.25 1.10  0.15 1.02  0.24 d d
PNP 1.04  0.29 1.86  0.97 1.09  0.54 [** d
POLR3B 1.14  0.53 1.07  0.26 1.12  0.58 d d
PRUNE 1.02  0.34 1.42  0.34 1.37  0.63 [** [*
Student t test *p < 0.05 and **p < 0.01.
Key: AD, Alzheimer’s disease; C, control; GUS-b, b-glucuronidase; mRNA, messenger RNA; PCR, polymerase chain reaction.
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published works (Sana et al., 2008).
2.7. Pathway analyses and statistics
Pathway analysis was performed using Metaboanalyst platform
(Xia et al., 2012). Non-targeted metabolomics analyses were carried
out using theMassHunterMass Proﬁler Professional Software (Agilent
Technologies, Barcelona, Spain). Other statistical calculations were
performed using the SPSS software (SPSS, Chicago, IL, USA). Normality
of variables’ distributionwas checked with the KolmogoroveSmirnoff
test. Differences in amount of molecules between groups were
analyzed with 1-way ANOVA using Benjamini-Hochberg multiple
testing correction. Ap< 0.05 levelwas selected as thepoint ofminimal
statistical signiﬁcance in every comparison. Graphics were created
with Graph Pad Prism (version 4.0; La Jolla, CA, USA).
3. Results
3.1. Functional genomic analysis detects deregulation of purine
metabolism in AD entorhinal cortex
Messenger RNA samples fromAD (n¼ 5) and age-matched controls
(n ¼ 5) were hybridized to an Affymetrix Human Exon 1.0 ST Array,
which interrogates over 1 million exon clusters within the known and
predicted transcribed regions of the entire genome. We found a differ-
ential expression of genes belonging to the Kyoto Encyclopedia of Genes
and Genomes (KEGG) (Kanehisa and Goto, 2000) pathway “Purine
Metabolism” (KEGG:00230). Modiﬁcation of transcriptional proﬁles for
thesepurinegenes inADwasevidencedon theheatmap representation
of signiﬁcantly regulated transcripts at probability of p < 0.05 (Fig. 1).
3.2. mRNA expression of purine metabolism enzymes in the human
entorhinal cortex in AD at stages III-IV and V-VI
mRNA expression of 23 genes involved in purine metabolism
was analyzed with TaqMan PCR. The symbol and names of the
enzymes are shown in Table 2.No differences were found in the mRNA expression levels of
purine metabolism-related enzymes in the entorhinal cortex of AD
stages III-IV when compared with controls.
We found downregulation of APRT, DGUOK, POLR3B, ENTPD3,
AK5, NME1, NME3, NME5, and NME7, whereas ENTPD2 mRNAs
were upregulated in the entorhinal cortex of AD stages V-VI of
Braak and Braak (Fig. 2). mRNA expression values for all probes
normalized with GUS-b in entorhinal cortex in AD stages V-VI and
control cases are displayed in Table 3.3.3. mRNA expression of purine metabolism enzymes in the human
frontal cortex area 8 in AD at stages III-IV and V-VI
To assess possible regional differences in the expression of genes
related to purine metabolism in AD the frontal cortex was analyzed
in similar cases.
In contrast to AD entorhinal cortex at stages III-IV, ENTPD2,
NME3, PNP, and PRUNE mRNAs were signiﬁcantly upregulated in
the AD frontal cortex area 8 at stages III-IV compared with controls
(Fig. 3).
Regarding stages V-VI, AK5 mRNAwas found to be differentially
downregulated and PRUNE mRNA upregulated in the frontal cortex
when compared with controls (Fig. 3). mRNA expression values in
the frontal cortex for all probes normalized with GUS-b are shown
in Table 4.3.4. mRNA expression of purine metabolism enzymes in the
precuneus in AD at stages III-IV and V-VI
APRT, DGUOK, ENTPD3, POLR3B, NME3, and NME7 mRNAs were
signiﬁcantly downregulated, and ENTPD2mRNA upregulated in the
precuneus in AD stages III-IV in relation to controls (Fig. 4).
With regard to AD stages V-VI, NME3, NME4, and NME7 mRNA
expression was decreased in comparison with controls when
normalized with GUS-b (Fig. 4). mRNA expression values in the
precuneus for all probes normalized with GUS-b are shown in
Table 5.
Fig. 4. mRNA expression levels of deregulated genes of purine metabolism in the precuneus in control and AD cases as determined by TaqMan PCR assays. Expression values for the
distinct probes are normalized with GUS-b. Mean fold-change values of each group are compared with Student t test and differences are considered statistically signiﬁcant at * p <
0.05 and ** p < 0.01. (A) Comparison between controls and AD stages III-IV; (B) Comparison between controls and AD stages V-VI. Abbreviations: AD, Alzheimer’s disease; GUS-b, b-
glucuronidase; mRNA, messenger RNA; PCR, polymerase chain reaction.
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To extend and validate transcriptomic ﬁndings we performed
untargeted metabolomics in selected entorhinal cortex samples. To
learn about early metabolomics alterations, AD stages I-II were
added to the study. First of all, using those molecules present in at
least 75% of samples in the same group, hierarchical clustering
analyses (Fig. 5A) showed the global proﬁling of the samples and
the main differences between them, and demonstrated that AD
staging is a major factor for metabolomic proﬁle discrimination.
Thus, samples from control individual and stages V-VI of Braak and
Braak clustered perfectly, whereas those of stages I-II and III-IV
were more variable depending on the individual.
After metabolite identiﬁcation using an orthogonal approach
pathway analysis, one of the pathways with the most affected
metabolites was related to purine metabolism. Speciﬁcally, takingonly into account those molecules present in the database, 6
purine-related metabolites were seen to be affected by the disease
and also by the stage (Fig. 5B). Among these, deoxyguanosine,
guanine, and xanthosine changed at stages I-II of Braak and Braak
and altered values at later stages; modiﬁcations in the expression of
dGMP and glycine occurred at stages II-IV and persisted at stages V-
VI. Other metabolites marked advanced staging of AD, such as
inosine diphosphate (IDP). Globally, integrated biology showed a
marked deviation of purine metabolism enzymes and metabolites
in the entorhinal cortex in AD (Fig. 6).
4. Discussion
Global transcriptomics has identiﬁed deregulation of the purine
metabolism pathway in the entorhinal cortex in AD. The tran-
scriptomic studywas performed on 23ADcases at stages III-IV, 35 AD
Table 5
mRNA expression levels of total purine metabolism enzymes in control and AD cases in the precuneus as determined by TaqMan PCR assays. Expression levels of controls, AD
III-IV, and AD V-VI cases using GUS-b for normalization
Probe C AD III-IV C* AD V-VI C versus AD III-IV C* versus AD V-VI
ADA 1.07  0.41 0.81  0.31 1.07  0.42 0.65  0.35 - -
AK1 1.02  0.18 1.17  0.09 1.00  0.10 1.15  0.40 -
AK2 1.01  0.12 0.98  0.07 1.03  0.29 0.80  0.22 - -
AK4 1.02  0.22 0.95  0.17 1.05  0.35 0.83  0.31 - -
AK5 1.02  0.23 0.98  0.15 1.06  0.39 0.90  0.30 - -
AK7 1.03  0.29 1.33  0.53 1.02  0.23 1.10  0.35 - -
APRT 1.02  0.24 0.72  0.27 NA NA Y* NA
DGUOK 1.02  0.21 0.79  0.15 1.03  0.28 0.81  0.23 Y* -
ENTPD1 1.01  0.15 0.91  0.23 1.04  0.16 0.87  0.21 - -
ENTPD2 1.01  0.17 1.28  0.24 1.04  0.29 0.90  0.31 [* -
ENTPD3 1.04  0.30 0.67  0.22 1.15  0.59 0.92  0.27 Y* -
NME1 1.02  0.23 1.01  0.18 1.01  0.16 0.93  0.33 - -
NME3 1.02  0.18 0.77  0.08 1.03  0.19 0.75  0.19 Y** Y*
NME4 1.01  0.18 1.06  0.29 1.04  0.30 0.72  0.16 - Y*
NME5 1.06  0.37 0.88  0.12 1.06  0.38 0.99  0.31 - -
NME6 1.02  0.20 0.89  0.12 1.02  0.20 0.81  0.17 - Y*
NME7 1.01  0.14 0.86  0.11 1.03  0.25 0.94  0.30 Y* -
NT5C 1.10  0.38 1.21  0.24 1.04  0.31 0.97  0.25 - -
NT5E 1.05  0.36 0.81  0.37 1.12  0.59 0.94  0.28 - -
NUDT1 1.03  0.28 1.03  0.15 1.04  0.32 1.13  0.19 - -
PNP 1.07  0.40 0.85  0.32 1.05  0.35 0.82  0.36 - -
POLR3B 1.03  0.25 0.63  0.16 1.03  0.26 0.93  0.31 Y** -
PRUNE 1.01  0.15 0.92  0.15 1.03  0.25 0.94  0.22 - -
Student t test *p < 0.05 and **p < 0.01.
Key: AD, Alzheimer’s disease; C, control; GUS-b, b-glucuronidase; mRNA, messenger RNA; NA, not available; PCR, polymerase chain reaction.
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and 3 cortical regionsdentorhinal cortex, frontal cortex area 8, and
precuneusdusing qRT-PCR. The selection of the 3 regions was based
on the early involvement of the entorhinal cortex when compared
with the frontal cortex area 8 (Braak and Braak, 1991) together with
positron emission tomography identiﬁcation of reduced cerebral
glucose metabolism in the precuneus in AD (Herholz et al., 2007).
Viewed globally, the following genes have been found to be
deregulated in AD when compared with controls: APRT, AK5, NME1,
NME3, NME4, NME5, NME6, NME7, PRUNE, DGUOK, ENTPD2, ENTPD3,
POLRB3, and PNP, although with variable extent depending on the
region and the stage of the disease. Adenine phosphoribosyl-
transferase (encoded by APRT) is involved in the synthesis of AMP
from adenine and guanosine monophosphate from guanine. APRT,
whose defect in humans causes Lesch-Nyhan disease, has been
recently implicated in Wnt signaling and presenilin-1 function
(Kang et al., 2011), known targets of AD (Lee et al., 2010), thus
reinforcing suspected links between purine metabolism and AD.
Adenylate kinase 5 (encoded by AK5), one member of the AK
family, participates in the phosphorylation of AMP to adenosine
diphosphate and dAMP to dATP (Dzeja and Terzic, 2009; Noma,
2005). In addition, adenylate kinase 5 interacts in brain with
14.3.3z complex (Angrand et al., 2006), a protein associated with
tau deposition in neuroﬁbrillary tangles (Qureshi et al., 2013).
The NME gene family encodes nucleotide diphosphate kinases
and is composed of 10 genes, the products of which are involved in
the phosphorylation of nucleotide diphosphates to form nucleotide
triphosphates (i.e., guanosine triphosphate, ATP, dGTP, dATP, and
dITP). This enzyme is especially present in the postsynaptic density
fraction, supporting its relationship with synaptic function.
Reduced mRNA expression of members of this family here identi-
ﬁed agrees with previous results suggesting their decrease in AD
(Kim et al., 2002) and in AD-related transgenic mouse models
(Liauw et al., 2002). In a close relationship with NME, PRUNE en-
codes prune exopolyphosphatase which participates in the meta-
bolism of guanosine pentaphosphate and tetraphosphate in
bacteria and is involved in the ability of RNA polymerases to initiate
transcription. The human homolog h-PRUNE probably has similarfunctions. In addition to this metabolic function, it has also been
involved in glyogenesis (Bilitou et al., 2012) and in brain develop-
ment (Carotenuto et al., 2006), being mechanistically linked to NME
in memory conservation (Li et al., 2012).
Deoxyguanosine kinase (encoded by DGUOK) phosphorylates
purine deoxyribonucleosides in the mitochondrial matrix
(Desvignes et al., 2009; Johansson et al., 2001; Jüllig and Eriksson,
2000). Its loss causes a complex mitochondriopathy with cerebral
involvement (Mandel et al., 2001). DGUOK mutations have been
reported in adult patients with mitochondrial DNA multiple de-
letions suffering from cognitive impairment (Ronchi et al., 2012).
Furthermore, this enzyme is implicated in the regulation of neurite
outgrowth (Loh et al., 2008).
ENTPD2 and ENTPD3, encoded by the genes ENTPD2 and
ENTPD3, are 2 of the 8 members of ecto-nucleoside triphosphate
diphosphohydrolases which hydrolyze the terminal phosphate
group of nucleoside triphosphates and diphosphates, yielding di-
phosphates and monophosphates, respectively (Yegutkin, 2008).
ENTPD2 and ENTPD3 dephosphorylate triphosphosphate nucleo-
sides (guanosine triphosphate, AMP, and IDP) to their mono-
phosphate form. Nucleoside triphosphate diphosphohydrolases are
enzymes controlling extracellular ATP concentration, and their
products are physiological activators of P1 (adenosine-activated
type I receptors: A1, A2A, A2B, and A3), P2 (nucleotide-activated
type 2 ligand-gated or ionotropic P2X ion channels), and metabo-
tropic P2Y receptors (Al-Rashida and Iqbal, 2014).
POLR3B encodes polymerase (RNA) III (DNA directed) poly-
peptide B which is the largest subunit of RNA polymerase III
responsible for synthesizing transfer and small ribosomal RNAs.
Our results are in line with previous reports showing abnormal
POLR3BmRNA splicing (Bai et al., 2013) and reduced POLR3BmRNA
levels (Husseman et al., 2001).
Finally, purine nucleotide phosphorylase, encoded by PNP,
reversibly catalyzes the phosphorolysis of purine nucleosides.
Interestingly, G151S polymorphism in this gene is associated with
faster progression of cognitive decline in AD (Tumini et al., 2007).
Regarding the entorhinal cortex, 10 of 24 genes analyzed are
abnormally regulated in AD at stages V-VI; only one of them
Fig. 5. Metabolomics of the entorhinal cortex in controls and AD stages I-II, III-IV, and V-VI of Braak and Braak. (A) Heat map representation of hierarchical clustering of molecular
features found in sample. Each line of this ﬁgure represents an accurate mass, colored by its abundance intensity normalized to internal standard and baseline to median/mean
across the samples. The scale from 11.8 (blue) to 11.8 (red) represents this normalized abundance in arbitrary units. (B) Normalized levels of purine-related pathway metabolites,
with a, b, and c superindex indicating homogeneous subsets of metabolites by 1-way ANOVA Tukey post hoc analyses. Abbreviations: AD, Alzheimer’s disease; ANOVA, analysis of
variance. (For interpretation of the references to color in this ﬁgure, the reader is referred to the web version of this article.)
Fig. 6. Simpliﬁed representation of the purine metabolism pathway showing deregulated enzymes and metabolites in human entorhinal cortex in AD compared with control
samples. Enzymes found to be upregulated are colored in green, those with decreased expression levels are displayed in red and enzymes with unvarying expression levels are
shown in gray. Metabolites with statistical differential levels are encircled in blue. Abbreviation: AD, Alzheimer’s disease. (For interpretation of the references to color in this ﬁgure,
the reader is referred to the web version of this article.)
B. Ansoleaga et al. / Neurobiology of Aging xxx (2014) 1e13 11
B. Ansoleaga et al. / Neurobiology of Aging xxx (2014) 1e1312(ENTPD2) is upregulated, whereas the other 9 are downregulated. A
similar pattern was found involving only 7 of the 10 genes abnor-
mally regulated in the entorhinal cortex also deregulated in the
precuneus in AD at stages III-IV; ENTPD2 is upregulated and the
other 6 downregulated. Curiously, only 2 new genes appear down-
regulated in the precuneus at stages V-VI. A very different proﬁle
occurs in the frontal cortex area 8 where 4 genes appear upregu-
lated and none downregulated at stages III-IV, whereas only 1 gene
is downregulated and none upregulated at stages V-VI.
Together, these ﬁndings indicate similar proﬁles of gene
deregulation in AD, albeit with different timings, in the entorhinal
cortex and precuneus. The frontal cortex has a different regulation
proﬁle of genes involved in purine metabolism. These differences
are not dependent on the stage of neuroﬁbrillary tangle formation,
as the precuneus and frontal cortex area 8 have no neuroﬁbrillary
tangle pathology at stages III-IV of Braak and Braak, whereas the
entorhinal cortex is heavily affected by neuroﬁbrillary tangles at
stages III-IV. The regional distribution of senile plaques in the
progression of AD (Braak and Braak, 1991, 1999) does not match the
regional deregulation of genes controlling purine metabolism.
To learn about the consequences of altered gene regulation of
purine metabolism using a completely different technique, mass-
spectrometric based metabolomics was applied to the study of
the entorhinal region at stages I-II, III-IV, and V-VI of Braak and
Braak. It is important to stress that the half-life of several metab-
olites is measured in seconds, minutes, and a few hours. In conse-
quence, metabolomics applied to postmortem human brain has
beneﬁts, as it can reveal long-lasting metabolites, but also limita-
tions, as short-lived species vanish during the agonic stage and
especially with the postmortem delay. Even considering these ca-
veats, several altered metabolites have been identiﬁed in the en-
torhinal cortex including deoxyguanosine, dGMP, guanine, glycine,
xanthosine, and IDP, thus supporting the idea that deregulation of
genes involved in purine metabolism has functional effects. Inter-
estingly, metabolomics in the entorhinal cortex has shown detect-
able changes in the expression levels of deoxyguanosine,
xanthosine and guanine at stages I-II, followed by modiﬁcations in
dGMP and glycine at stages III-IV. The explanation for the greater
sensitivity of metabolomics than of transcriptomics to AD in early
stages of AD may involve technical reasons or differing sensitivities
to the disease of the outcome variable. Recent data show that
metabolomics ﬁndings exceed what could be discerned from
downstream analyses with transcriptomics (Tsai et al., 2013). In this
line, posttranscriptional modiﬁcation of enzymes could impinge on
relevant changes in activity, without detectable alterations in
mRNA transcripts, as exempliﬁed by circadian regulation of enzyme
activity (Robles et al., 2014).
In conclusion, changes in purine metabolism identiﬁed in the
present study may affect the complex equilibrium between intra-
cellular nucleoside triphosphates and the depending metabolites
and products, including their export to extracellular space as neu-
rocrine factors in AD. The regional differences observed here point
to the need for considering regional speciﬁcities as markers of
regional vulnerability.
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